Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab for Desensitization in Kidney Transplant Candidates
NCT04204980Phase 2Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Feb 2020
- Primary completion
- Jun 2023
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of daratumumab in Allosensitization, sponsored by Assistance publique - Hôpitaux de Paris. Started Feb 2020; status: completed.
02
Drugs
daratumumab
03
Conditions
Allosensitization
Beyond the preview
Go deeper on NCT04204980.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04204980.